A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
01/03/2022at 13:34

Sonova completes Alpaca Audiology acquisition

Swiss Sonova has now fully taken over US-based hearing aid provider Alpaca Audiology.
Photo: Sonova / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

The acquisition process of US-based hearing aid provider Alpaca Audiology is now completed, the new owner, Swiss hearing aid giant Sonova, announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Arnd Kaldowski, CEO at Sonova | Photo: Sonova / PR/Daniel Hager Photography & Film

    Sonova acquires US-based hearing aid provider for USD 310m

    For subscribers

  • Photo: Demant / PR

    Demant and Sonova take Veterans Affairs market shares in January

    For subscribers

  • Hearing aid market in US grew by 37 percent in 2021

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”
  • Is William Demant Invest seeking hostile takeover of GN? Three scenarios in play
  • Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Application Manager

  • Head of International Sales

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Clinical Operational Associate

See all jobs

Jobs

  • Application Manager

  • Application Manager

  • Head of International Sales

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Clinical Operational Associate

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge